A Phase 1 interventional study of Tretinoin Gel Microsphere, 0.04% and RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.04% in Acne Vulgaris, sponsored by Sun Pharmaceutical Industries, Inc.. Completed at 1 site in United States. Open to participants aged 12 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-13.
Sponsored by Sun Pharmaceutical Industries, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Acne Vulgaris by Sun Pharmaceutical Industries Limited — none open to participants now, 1 under way, none of them phase 3. Acne Vulgaris · Sun Pharmaceutical Industries Limited.
Among the 30 studies in Acne Vulgaris by Sun Pharmaceutical Industries Limited, this one is the 7th largest by enrollment, is the only one that started in 2025, is one of 21 in phase 1, and was the 30th registered.
795 studies on the registry are indexed under Acne Vulgaris; 96 are open to participants now.
Browse Acne Vulgaris studies →None of the 30 studies in Acne Vulgaris by Sun Pharmaceutical Industries Limited is open now. The open studies under Acne Vulgaris, anywhere →
Of the 48 Acne Vulgaris studies recruiting now, 17 (35%) set no upper age limit and 30 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 12 Years to 40 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,043 is above the median of 70 across 676 interventional studies indexed under Acne Vulgaris.
Median enrollment 727 across the 30 interventional studies. Of the 29 that completed or were terminated, 8 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Sun Pharmaceutical Industries, Inc., one of the names counted as Sun Pharmaceutical Industries Limited. Under that name alone:
Sun Pharmaceutical Industries, Inc. is the lead sponsor of 9 studies on the registry; 3 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 30 studies in Acne Vulgaris by Sun Pharmaceutical Industries Limited, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To demonstrate the efficacy, therapeutic equivalence and safety of tretinoin gel microsphere, 0.04% (Sun Pharmaceutical Industries, Inc.) and RETIN-A MICRO ® (tretinoin) gel microsphere, 0.04% (Reference Listed Drug) in the treatment of acne vulgaris.
A multi-center, double-blind, randomized, placebo-controlled, parallel-group study, comparing Tretinoin Gel Microsphere, 0.04% (Sun Pharmaceutical Industries, Inc.) and RETIN-A MICRO ® (Tretinoin) Gel Microsphere, 0.04% (Reference Listed Drug) in the treatment of acne vulgaris.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The investigational product will be applied topically to the affected areas of the face lightly once daily at bedtime, avoiding the eyes, mouth, and other mucous membranes for 84 consecutive days.
Drug: Tretinoin Gel Microsphere, 0.04%
The investigational product will be applied topically to the affected areas of the face lightly once daily at bedtime, avoiding the eyes, mouth, and other mucous membranes for 84 consecutive days.
Drug: RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.04%
The investigational product will be applied topically to the affected areas of the face lightly once daily at bedtime, avoiding the eyes, mouth, and other mucous membranes for 84 consecutive days.
Drug: Placebo Control
The investigational product will be applied topically to the affected areas of the face lightly once daily at bedtime, avoiding the eyes, mouth, and other mucous membranes for 84 consecutive days.
Also known as: Test Product
The investigational product will be applied topically to the affected areas of the face lightly once daily at bedtime, avoiding the eyes, mouth, and other mucous membranes for 84 consecutive days.
Also known as: Reference Product
The investigational product will be applied topically to the affected areas of the face lightly once daily at bedtime, avoiding the eyes, mouth, and other mucous membranes for 84 consecutive days.
Also known as: Vehicle of the test product
Demonstrate & evaluate the therapeutic, equivalence and safety of the investigational product
Mean Percentage change in the inflammatory (papules and pustules) \& non-inflammatory (comedones) lesion counts
Time frame: Baseline to Week 12
Plan to share: No
No publications or documents are linked to this record.
Ran from Aug 2025 to primary completion in Dec 2025, 4 months.
Of 44 industry-sponsored phase 1 interventional studies under Acne Vulgaris, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 7. This study's 4 months is close to that.
Counting every sponsor, half of 51 studies reached it within 5 months; a quarter within 2 and three quarters within 10.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sun Pharmaceutical Industries, Inc. →